1. Dosage regimen and toxicity risk assessment of linezolid in sepsis patients.
- Author
-
Dou, Linjie, Meng, Dandan, Dong, Yalin, Chen, Lihong, Han, Xinyan, Fan, Di, and Dong, Haiyan
- Subjects
- *
SEPSIS , *DRUG monitoring , *MONTE Carlo method , *RISK assessment , *LINEZOLID - Abstract
• An AUC 24 /MIC of 100 was required to achieve a bacterial51 eradication rate of 80% for sepsis patients treated with linezolid. • An 800 mg/12 h (safety probability 66.8%) dosing regimen was appropriate for sepsis patients with normal renal function or mild kidney damage. • There is a high thrombocytopenia probability with 600 mg/12 h for sepsis patients on CRRT, so dosing should be adjusted based on TDM. Significant alterations in the pharmacokinetic characteristics of linezolid are often seen in sepsis patients. The study aimed to identify a target pharmacokinetics/pharmacodynamics (PK/PD) index of the efficacy of linezolid treatment, and to estimate the optimum dosage regimen of linezolid in sepsis patients. The PK data were modeled using the one-compartment model, which determined the target PK/PD index for successful treatment by logistic regression. The probability of thrombocytopenia was identified by establishing a logistic model. Different dosing regimens were evaluated using Monte Carlo simulation. Reaching 80% bacterial eradication required an AUC 24 /MIC of 100, which defined the therapeutic target. The proposed regimen to attain a cumulative fraction of response ≥80% was 800 mg/12 h (safety probability 66.8%) for sepsis patients with normal renal function or mild kidney damage. By contrast, the target cumulative fraction of response was attained with a standard dosing regimen in sepsis patients on continuous renal replacement therapy [600 mg/12 h (safety probability 49.7%)]. This study identified different dosing strategies to achieve target linezolid PK/PD values according to whether sepsis patients were treated with continuous renal replacement therapy. Due to the high incidence of thrombocytopenia in sepsis patients on continuous renal replacement therapy, therapeutic drug monitoring should be encouraged for optimizing linezolid exposure in sepsis patients. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF